- $36.71bn
- $43.10bn
- $9.89bn
FDA approves at-home starter dose of Eisai-Biogen Alzheimer's drug (updated)
Refile: FDA approves at-home starter dose of Eisai-Biogen Alzheimer's drug
Biogen rises after FDA clears at-home use of Alzheimer's drug
Brief: FDA Approves New Leqembi Subcutaneous Dosing Regimen For Alzheimer's
U.S. STOCKS ON THE MOVE-Circle Internet, Solaris Energy, Fermi
U.S. STOCKS ON THE MOVE-Circle Internet, Solaris Energy, Fermi
U.S. STOCKS ON THE MOVE-Circle Internet, SK Hynix, Solaris Energy
U.S. STOCKS ON THE MOVE-SK Hynix, Delta Air, Circle Internet
Biopharma dealmaking on way to record year, says HSBC
U.S. RESEARCH ROUNDUP- BlackRock, Eli Lilly, Goldman Sachs
U.S. RESEARCH ROUNDUP-East West Bancorp, First Citizens Bancshares, UMB Financial
Health Rounds: Old cancer drug may help restore fertility for certain women
U.S. STOCKS ON THE MOVE-FactSet, Moderna, Goldman Sachs
U.S. STOCKS ON THE MOVE-Biogen, Incyte, Quantum Cyber
Biogen rises; co scales back drug programs acquired through $5.6 bln Apellis deal
Biogen scales back Apellis programs, trims research roles after $5.6 billion buyout
Brief: Biogen To Pause Or Terminate Investment In Majority Of Legacy Apellis Research Programs, Says Spokesperson
Deals of the day-Mergers and acquisitions
Deals of the day-Mergers and acquisitions